Susanna Fenu

Rome, 00184, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers.

Journal: Cancers

Published: March 28, 2025

Luspatercept in lower-myelodysplastic syndromes (MDS): Real-world data from the Gruppo Romano-Laziale Mielodisplasie (GROM-L) and review of literature.

Luspatercept in lower-myelodysplastic syndromes (MDS): Real-world data from the Gruppo Romano-Laziale Mielodisplasie (GROM-L) and review of literature.

Journal: Leukemia research

Published: March 09, 2025

Long-term Persistence of Dysplastic Features in Patients with Acute Promyelocytic Leukemia Treated with All-trans Retinoic Acid and Arsenic Trioxide.

Long-term Persistence of Dysplastic Features in Patients with Acute Promyelocytic Leukemia Treated with All-trans Retinoic Acid and Arsenic Trioxide.

Journal: Mediterranean journal of hematology and infectious diseases

Published: March 03, 2025

The role of morphology in diagnosing MDS with Non-clonal cytopenias.

The role of morphology in diagnosing MDS with Non-clonal cytopenias.

Journal: Leukemia research

Published: February 13, 2025

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile.

Journal: Annals of hematology

Published: May 08, 2023

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Journal: Blood cancer journal

Published: June 22, 2022

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?

Journal: Journal of clinical medicine

Published: March 01, 2022

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.

Journal: HemaSphere

Published: May 13, 2020

Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study.

Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study.

Journal: Scientific reports

Published: June 03, 2019

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS).

Journal: British journal of haematology

Published: November 09, 2018

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

Journal: Leukemia research

Published: July 03, 2018

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.

Journal: American journal of hematology

Published: June 19, 2017

Showing 1-12 of 28

Last Updated: 09/26/2026